| Document |
Document Title |
|
WO/2003/080075A1 |
An ameliorant for the chemical treatment of cancer which contains a chromanol glycoside represented by the following general formula (1): (1) wherein R1, R2, R3, and R4 are the same or different and each represents hydrogen or lower alky...
|
|
WO/2003/073988A2 |
Disclosed are glycosides, orthoester glycosides and glycuronamides of fluoxetine and analogs thereof to treat conditions and diseases such as depression.
|
|
WO/2003/072489A1 |
A microfine self-aggregate having a unique high-order structure, which is formed using an oligosaccharide as a sugar chain. The microfine self-aggregate comprises an O-glycoside type glycolipid having a structure represented by the follo...
|
|
WO/2003/072858A1 |
Fibrous nano self−assemblies consisting of o−glycoside glycolipids each having a structure represented by the following general formula: wherein G represents glycosyl&semi and R represents C12−18 hydrocarbyl&semi characterized in t...
|
|
WO/2003/070703A2 |
The present invention relates to hydroxylated indirubin derivatives having the formula (I) wherein the group R represents a straight-chain or branched-chain alkyl group or a straight chain or branched-chain alkoxy group each having 1 to ...
|
|
WO/2003/070182A2 |
The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.
|
|
WO/2003/068789A1 |
Inositol phosphate esters and conjugates formed between the compounds and a coupling partner are disclosed, in particular compounds based on a myo−inositol which is substituted at position 1 with a phosphate ester group, at position 2 ...
|
|
WO/2003/066648A1 |
The present invention relates to heterodimeric conjugates of neomycin-oxazolidinone of formula 1, their preparation and their use. Because of their heterodimeric structure, they can recognize both stems and loops of the RNA motif and sho...
|
|
WO/2003/065806A1 |
This invention provides compounds containing a 2-deoxy-2-amino-$g(b)-D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group. The invention further provides methods for inducing an immune response usin...
|
|
WO/2003/067209A2 |
The present invention relates to the design and synthesis of homogeneous A-L-P constructs, which contain a hepatic ligand to direct an oligomer or 'payload' to a heptatocyte intracellularly via a receptor-mediated, ligand-directed pathway.
|
|
WO/2003/066065A1 |
Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses...
|
|
WO/2003/066059A1 |
4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-
yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutical acceptable salt thereof can be used in the treatment of neuroblastoma. The invention also relates to a combination ...
|
|
WO/2003/064378A2 |
The invention relates to the compounds of formula (I) or to the pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. The inventive compounds can be used to inhibit factor Xa and to pr...
|
|
WO/2003/064440A1 |
The invention relates to the compounds of formula (I) or to the pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. The inventive compounds can be used to inhibit factor Xa and to pr...
|
|
WO2003048375B1 |
Hybrid glycosylated products such as polyketides and peptides are produced by transforming a host cell with (a) a gene cassette for synthesising an activated sugar and (b) nucleic acid encoding a glycosyltransferase (GT). The cell also p...
|
|
WO/2003/059298A1 |
The invention relates to the alk(en)yl olligoglycoside betaine ester quaternaries of the formula R1O(G)nOCOCR2R3NR4R5R6 (I), wherein R1 represents an alk(en)yl group with 4 to 22 carbon atoms, G represents a sugar residue with 5 to 6 car...
|
|
WO/2003/057250A1 |
The invention relates to a therapeutic system comprising (i) a radiolabelled antibody, which binds selectively to polymorphic epithelial mucin (PEM) such as the monoclonal antibody HMFG−1, and (ii) a chemotherapeutic agent, such as Tax...
|
|
WO/2003/057896A1 |
The present invention relates to a process for preparation of a product compound of the Formula (I), where R1 is an acyl group, R2 is H, an N−alkylated amino sugar, or a non−basic sugar moiety, and R3 is H, OH, or OCH3. The process i...
|
|
WO/2003/057687A1 |
The present invetion relates to a process for preparation of a product compound of formula (I), where R¿1? is an acyl group. The process involves reacting a starting compound of formula (II), with an activated acyl donor compound in the...
|
|
WO/2003/055497A1 |
The present invention relates to gangliosides derived or isolated from buffalo milk, skimmed buffalo milk, buffalo milk serum or derivatives of either. Buffalo milk is reported to comprise gangliosides that are not contained in bovine mi...
|
|
WO/2003/055861A1 |
A compound which is a benzocyclodecane of the formula I wherein: ----- at positions 8-9 and 11-12 independently represents a single or double bond, -R1 is &equals O, or -OR7, R7 is H, C1-C7 alkanoyl, benzoyl, C1-C10 alkyl, C2-C10 alkenyl...
|
|
WO/2003/054122A2 |
Disclosed is a method for bleaching aqueous alkyl polyglycoside preparations with the aid of peroxygen compounds, characterized in that the bleaching is carried out in the presence of 4-15 % peroxygen compounds in relation to the active ...
|
|
WO/2003/053368A2 |
The invention relates to compounds, pharmaceutical compositions and use of compounds of the general formula (I), or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
|
|
WO/2003/053987A1 |
The invention concerns surfactant compositions and a method for preparing same. The method consists in reacting a pentose with an alkadiene in the presence of a palladium catalyst activated by a phosphine, and is characterized in that th...
|
|
WO/2003/051889A1 |
A novel sordarin derivative was isolated from fungal cultures. The compound is useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops. Two novel cultur...
|
|
WO/2003/051864A1 |
The invention relates to compounds, formulations, drinks, foodstuffs, methods and therapeutic uses involving, containing, comprising, including and/or for preparing isoflavone conjugate compounds and analogues thereof. More preferably th...
|
|
WO/2003/047499A2 |
An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine deri...
|
|
WO/2003/044033A1 |
Immunosuppressants each containing as the active ingredient at least one member selected from the group consisting of compounds represented by the general formula (1) and pharmaceutically acceptable salts thereof: (1) wherein R101 is an ...
|
|
WO/2003/044032A1 |
A sugar derivative which has altered properties of a cyclic tetrasaccharide so as to expand the range of applications of the compound represented by the chemical formula (1); a composition containing the derivative; and a process for pro...
|
|
WO/2003/043656A1 |
A drug for preventing vascular restenosis which contains as the active ingredients compounds inactivating &agr 1−portease inhibitor and &agr −2 macroglobulin relating to the onset of vascular restenosis following coronary interventio...
|
|
WO/2003/044034A1 |
The present invention relates to heterodimeric conjugates of neomycin-chloramphenicol of formula 1, their preparation and their use. Because of their heterodimeric structure, they can recognize both stem and loop of RNA motif and show bi...
|
|
WO/2003/043613A2 |
Glycosides of diacylglycerol, e.g. 3-$g(b)-D-galactopyranosyloxy-2-(octadeca-9$i(Z),12$i(Z),15$
i(Z)-trienoyloxy)propanyl octadeca-9$i(Z),12$i(Z),15$i(Z)-trienoate (GOPO) (A), which was isolated from extracts of rose-hips by activity gui...
|
|
WO/2003/040104A1 |
The invention relates to a compound of general formula (I): X - L - Y, in which: X and Y are pharmaceutically active moieties which may be the same or different; and L is a linker which is an optionally substituted saturated or unsaturat...
|
|
WO/2003/039231A2 |
The use of compounds of the formula (I) and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are defined in the application.
|
|
WO/2003/040127A1 |
Mono-fluorinated and di-fluorinated benzothiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as we...
|
|
WO/2003/037907A1 |
Maltitol crystals containing crystals of a saccaride except maltitol, wherein particles having a particle size of 20 to 50 meshes obtained by pulverization and classification thereof have a loose apparent specific gravity greater than 0....
|
|
WO/2003/035657A2 |
The invention relates to alkylpolyglycosides having formulae: HO-R-O(X)¿r? or (X)¿s?-OR-O-(X)¿t?, wherein R denotes a linear or branched alkyl radical having between 6 and 12 carbon atoms. The invention also relates to the use of said...
|
|
WO/2003/035897A2 |
This invention provides new methods for detecting enzyme activity using enzyme substrates comprising an enzyme cleavable portion and a chromogenic portion. The enzyme cleavable portion is a β-D-ribofuranosyl group and the chromogenic po...
|
|
WO/2003/035896A2 |
This invention provides novel chromogenic enzyme substrates which are indoxyl β-D-ribofuranosides. A process for their production is provided. Methods for detecting β-D-ribofuranosidase activity are given. The advantages of these novel...
|
|
WO/2003/035672A1 |
The present invention relates to a biomolecule squaric acid monoamide conjugate of formula (I), as presented in the claims, and to a method for non-polar extraction of a biomolecule squaric acid monoamide conjugate of formula (I), as pre...
|
|
WO/2003/035660A1 |
A stabilized amrubicin hydrochloride composition which comprises 3 to 8 wt.% water and 92 to 97 wt.% amrubicin hydrochloride&semi and a method of storing amrubicin hydrochloride.
|
|
WO/2003/035659A1 |
An improved process for the purification of crude aqueous solutions of acarbose by passing such solutions through a strong acid cation-exchange resin, saturating such resin and recovering as an eluate a substantially pure acarbose soluti...
|
|
WO/2003/035661A1 |
The invention relates to compounds having the following formula (I), in which: R¿a? represents a sugar moiety, an arylamino group, or an alkyl group comprising at least one amino group, R¿b? represents an halogen atom, an halogenoalkyl...
|
|
WO/2003/032905A2 |
Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozo...
|
|
WO/2003/030820A2 |
Disclosed herein are pseudopterosin compounds obtained from Symbiodinium spp. symbionts. Also disclosed are methods of obtaining, isolating, purifying or preparing at least one pseudopterosin compound comprising obtaining, isolating, pur...
|
|
WO/2003/031460A1 |
The object of the invention is a method for the production of ethers from sugars C1-C8 alcohols. According to the invention, etherification is carried out by performing reactive distillation in a heterogeneous catalyst. The invention mak...
|
|
WO2003000709A9 |
the invention relates to Siglec inhibitors that have an increased affinity for the receptor molecule. The Siglec inhibitors provided by the invention are preferably selective of a given Siglec molecule. The invention further relates to m...
|
|
WO/2003/024583A1 |
A water dispersible colloidal system in the form of generally spherical matrix type particles and of sizes typically in the range of from 50 to 500 nm, called nanoparticles, and a process for the preparation of such systems. The system i...
|
|
WO/2003/025017A1 |
A crystalline composition comprising a crystal of the IL-6 receptor I chain is provided. Also provided are methods of using the crystal and related structural information to screen for and design compounds that interact with IL-6R, or va...
|
|
WO2002094019A9 |
The invention provides compositions containing a highly purified antiendotoxin compound and methods of preparing and using such compositions.
|
